A case of remission from pre-diabetes following intermittent hypoxic training

Fuller, Nicholas R.; Courtney, Rosalba

doi:10.1016/j.orcp.2016.05.008

Cited by 8 publications

(8 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IHC improves glycemic control in patients with type 2 diabetes, reducing blood glucose and postprandial glucose tolerance after one session (45). These findings were confirmed with longer IHC protocols in glucose-intolerant subjects (56,160). Importantly, the improvements in glycemic control persisted and were still apparent 1 mo later.…”

Section: Ihc Produces a Spectrum Of Benefits In Patients With Diabetesmentioning

confidence: 66%

“…NO also limits infiltration by neutrophils, reducing again the opportunity for both occlusive and oxidant damage during I/R (159). Aside from these major influences, NO also activates a variety of antistress (109), antioxidant (39,56), and antiapoptotic adaptations (104,197).…”

Section: Role Of No In Ihc-mediated Cardioprotectionmentioning

confidence: 99%

“…Could IHC be safely self-administered unsupervised? In this regard, there are already available a variety of devices for self-administration of IHC to enhance athletic performance (56,163). Finally, the cost of such a long-term clinical trial would be significant.…”

Section: Potential Clinical Applications Of Ihc and Impediments To Their Implementationmentioning

confidence: 99%

“…IHC appears safe, is consistently beneficial, noninvasive, practical, and potentially inexpensive and thus may merit serious consideration as a therapeutic modality. The most powerful argument for applying IHC in clinical settings is the mounting evidence of the safety and efficacy of IHC in patients with chronic illnesses (27,46,56,58,100,101,160,178). We hope this review will broaden the perspective of researchers, clinicians, and stakeholders to reconsider the clinical potential of IHC.…”

Section: Potential Clinical Applications Of Ihc and Impediments To Their Implementationmentioning

confidence: 99%

See 3 more Smart Citations

Cardioprotection by intermittent hypoxia conditioning: evidence, mechanisms, and therapeutic potential

Mallet

Манухина

Ruelas

et al. 2018

American Journal of Physiology-Heart and Circulatory Physiology

View full text Add to dashboard Cite

The calibrated application of limited-duration, cyclic, moderately intense hypoxia-reoxygenation increases cardiac resistance to ischemia-reperfusion stress. These intermittent hypoxic conditioning (IHC) programs consistently produce striking reductions in myocardial infarction and ventricular tachyarrhythmias after coronary artery occlusion and reperfusion and, in many cases, improve contractile function and coronary blood flow. These IHC protocols are fundamentally different from those used to simulate sleep apnea, a recognized cardiovascular risk factor. In clinical studies, IHC improved exercise capacity and decreased arrhythmias in patients with coronary artery or pulmonary disease and produced robust, persistent, antihypertensive effects in patients with essential hypertension. The protection afforded by IHC develops gradually and depends on β-adrenergic, δ-opioidergic, and reactive oxygen-nitrogen signaling pathways that use protein kinases and adaptive transcription factors. In summary, adaptation to intermittent hypoxia offers a practical, largely unrecognized means of protecting myocardium from impending ischemia. The myocardial and perhaps broader systemic protection provided by IHC clearly merits further evaluation as a discrete intervention and as a potential complement to conventional pharmaceutical and surgical interventions.

show abstract

Section: Ihc Produces a Spectrum Of Benefits In Patients With Diabetesmentioning

confidence: 66%

Section: Role Of No In Ihc-mediated Cardioprotectionmentioning

confidence: 99%

Section: Potential Clinical Applications Of Ihc and Impediments To Their Implementationmentioning

confidence: 99%

Section: Potential Clinical Applications Of Ihc and Impediments To Their Implementationmentioning

confidence: 99%

See 2 more Smart Citations

Cardioprotection by intermittent hypoxia conditioning: evidence, mechanisms, and therapeutic potential

Mallet

Манухина

Ruelas

et al. 2018

American Journal of Physiology-Heart and Circulatory Physiology

View full text Add to dashboard Cite

show abstract

“…These protective effects were counteracted by the addition of an ATP-sensitive potassium (KATP) channel inhibitor, a mitochondrial KATP inhibitor, and a mitochondrial permeability transition pore opener. This study not only demonstrated the protective effect of CIH, but also verified for the first time that this effect was associated with KATP channels [ 14 ] In addition to the cardiac benefits, intermittent low-pressure hypoxic training has been shown to contribute to weight loss and glycemic control in prediabetic obese patients and is expected to help restore normal fasting glucose in prediabetic patients [ 47 ].…”

Section: Dual Nature Of Ihmentioning

confidence: 74%

Intermittent Hypoxia and Atherosclerosis: From Molecular Mechanisms to the Therapeutic Treatment

Luo

Zhu

et al. 2022

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Intermittent hypoxia (IH) has a dual nature. On the one hand, chronic IH (CIH) is an important pathologic feature of obstructive sleep apnea (OSA) syndrome (OSAS), and many studies have confirmed that OSA-related CIH (OSA-CIH) has atherogenic effects involving complex and interacting mechanisms. Limited preventive and treatment methods are currently available for this condition. On the other hand, non-OSA-related IH has beneficial or detrimental effects on the body, depending on the degree, duration, and cyclic cycle of hypoxia. It includes two main states: intermittent hypoxia in a simulated plateau environment and intermittent hypoxia in a normobaric environment. In this paper, we compare the two types of IH and summarizes the pathologic mechanisms and research advances in the treatment of OSA-CIH-induced atherosclerosis (AS), to provide evidence for the systematic prevention and treatment of OSAS-related AS.

show abstract